| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgeons | 16 | 2025 | 288 | 6.270 |
Why?
|
| Myocytes, Cardiac | 18 | 2024 | 670 | 4.710 |
Why?
|
| Coronary Artery Bypass | 38 | 2025 | 515 | 3.590 |
Why?
|
| Fibroblasts | 13 | 2024 | 852 | 3.570 |
Why?
|
| Cellular Reprogramming | 9 | 2024 | 128 | 3.360 |
Why?
|
| Genetic Therapy | 28 | 2024 | 715 | 3.200 |
Why?
|
| Neovascularization, Physiologic | 25 | 2024 | 195 | 2.830 |
Why?
|
| Cellular Reprogramming Techniques | 6 | 2020 | 15 | 2.770 |
Why?
|
| Vascular Endothelial Growth Factor A | 33 | 2024 | 331 | 2.740 |
Why?
|
| Cardiac Surgical Procedures | 30 | 2025 | 1156 | 2.720 |
Why?
|
| Cell Transdifferentiation | 7 | 2021 | 58 | 2.670 |
Why?
|
| General Surgery | 8 | 2025 | 225 | 2.290 |
Why?
|
| Genetic Vectors | 27 | 2024 | 896 | 2.090 |
Why?
|
| Myocardium | 17 | 2025 | 857 | 2.040 |
Why?
|
| Coronary Artery Disease | 19 | 2025 | 889 | 1.940 |
Why?
|
| Thoracic Surgical Procedures | 6 | 2021 | 106 | 1.840 |
Why?
|
| Heart Valve Prosthesis Implantation | 16 | 2024 | 422 | 1.820 |
Why?
|
| Adenoviridae | 25 | 2024 | 582 | 1.810 |
Why?
|
| Myocardial Infarction | 11 | 2023 | 998 | 1.770 |
Why?
|
| Biomedical Research | 5 | 2025 | 562 | 1.730 |
Why?
|
| Heart-Assist Devices | 11 | 2025 | 1013 | 1.690 |
Why?
|
| Gene Transfer Techniques | 19 | 2016 | 344 | 1.680 |
Why?
|
| Clinical Competence | 6 | 2024 | 1063 | 1.630 |
Why?
|
| Endothelial Growth Factors | 20 | 2002 | 38 | 1.610 |
Why?
|
| Myocardial Revascularization | 10 | 2014 | 100 | 1.510 |
Why?
|
| Heart Failure | 15 | 2025 | 2322 | 1.500 |
Why?
|
| Regeneration | 5 | 2020 | 225 | 1.500 |
Why?
|
| Lymphokines | 19 | 2002 | 61 | 1.450 |
Why?
|
| Salaries and Fringe Benefits | 2 | 2025 | 33 | 1.450 |
Why?
|
| Heart Diseases | 10 | 2023 | 501 | 1.420 |
Why?
|
| Thrombelastography | 3 | 2021 | 69 | 1.420 |
Why?
|
| T-Box Domain Proteins | 5 | 2022 | 120 | 1.400 |
Why?
|
| Humans | 212 | 2025 | 130342 | 1.390 |
Why?
|
| Postoperative Complications | 27 | 2025 | 3120 | 1.380 |
Why?
|
| Cardiopulmonary Bypass | 13 | 2025 | 359 | 1.380 |
Why?
|
| GATA4 Transcription Factor | 5 | 2024 | 35 | 1.370 |
Why?
|
| Coronary Disease | 14 | 2014 | 628 | 1.360 |
Why?
|
| Myocardial Ischemia | 12 | 2015 | 308 | 1.310 |
Why?
|
| Rats | 28 | 2024 | 3368 | 1.260 |
Why?
|
| Blood Transfusion | 8 | 2024 | 289 | 1.180 |
Why?
|
| Thoracic Surgery | 5 | 2022 | 163 | 1.150 |
Why?
|
| Regenerative Medicine | 2 | 2020 | 37 | 1.140 |
Why?
|
| Global Health | 4 | 2024 | 633 | 1.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2014 | 163 | 1.100 |
Why?
|
| Specialties, Surgical | 2 | 2021 | 90 | 1.070 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2025 | 136 | 1.070 |
Why?
|
| Heart Transplantation | 9 | 2025 | 830 | 1.060 |
Why?
|
| Efficiency | 3 | 2020 | 74 | 1.050 |
Why?
|
| Heart | 6 | 2023 | 659 | 1.050 |
Why?
|
| Patient Readmission | 12 | 2025 | 433 | 1.040 |
Why?
|
| Faculty, Medical | 3 | 2025 | 279 | 1.030 |
Why?
|
| Vascular Endothelial Growth Factors | 23 | 2021 | 47 | 1.020 |
Why?
|
| Mammary Arteries | 3 | 2018 | 31 | 0.990 |
Why?
|
| Aged | 72 | 2025 | 20859 | 0.940 |
Why?
|
| Surgical Procedures, Operative | 3 | 2019 | 223 | 0.910 |
Why?
|
| Endostatins | 1 | 2025 | 10 | 0.890 |
Why?
|
| Cognition Disorders | 5 | 2012 | 554 | 0.890 |
Why?
|
| Warm Ischemia | 4 | 2025 | 31 | 0.860 |
Why?
|
| Male | 114 | 2025 | 64409 | 0.850 |
Why?
|
| Cystatin C | 1 | 2025 | 71 | 0.850 |
Why?
|
| Assisted Circulation | 2 | 2014 | 23 | 0.840 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 319 | 0.830 |
Why?
|
| Transcription Factors | 11 | 2024 | 2423 | 0.820 |
Why?
|
| Myocardial Contraction | 4 | 2022 | 243 | 0.810 |
Why?
|
| Animals | 64 | 2024 | 33796 | 0.810 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 220 | 0.800 |
Why?
|
| Research Personnel | 1 | 2025 | 141 | 0.800 |
Why?
|
| Critical Illness | 5 | 2022 | 621 | 0.770 |
Why?
|
| Middle Aged | 71 | 2025 | 28366 | 0.770 |
Why?
|
| Acute Kidney Injury | 3 | 2025 | 695 | 0.770 |
Why?
|
| Aortic Valve Stenosis | 7 | 2022 | 350 | 0.760 |
Why?
|
| Exosomes | 1 | 2023 | 61 | 0.760 |
Why?
|
| Time Factors | 33 | 2025 | 6197 | 0.750 |
Why?
|
| Quality Improvement | 7 | 2025 | 706 | 0.730 |
Why?
|
| Laser Therapy | 6 | 2001 | 241 | 0.730 |
Why?
|
| Tretinoin | 2 | 2020 | 95 | 0.730 |
Why?
|
| Medicine | 1 | 2023 | 99 | 0.710 |
Why?
|
| Endothelium | 1 | 2021 | 60 | 0.700 |
Why?
|
| Societies, Medical | 4 | 2024 | 799 | 0.700 |
Why?
|
| Hospitals | 5 | 2022 | 437 | 0.690 |
Why?
|
| DNA, Complementary | 9 | 2013 | 425 | 0.680 |
Why?
|
| Periodicals as Topic | 2 | 2014 | 182 | 0.670 |
Why?
|
| Postoperative Hemorrhage | 5 | 2024 | 83 | 0.670 |
Why?
|
| Inventions | 3 | 2018 | 19 | 0.670 |
Why?
|
| Mitral Valve | 7 | 2024 | 244 | 0.660 |
Why?
|
| Treatment Outcome | 39 | 2025 | 12840 | 0.650 |
Why?
|
| Butyric Acid | 1 | 2020 | 7 | 0.650 |
Why?
|
| Cognition | 2 | 2021 | 810 | 0.650 |
Why?
|
| Organ Preservation | 3 | 2025 | 62 | 0.640 |
Why?
|
| Female | 89 | 2025 | 70331 | 0.630 |
Why?
|
| Pyrimidinones | 1 | 2020 | 62 | 0.630 |
Why?
|
| Heart Valve Prosthesis | 7 | 2022 | 299 | 0.630 |
Why?
|
| Thrombophilia | 1 | 2020 | 41 | 0.620 |
Why?
|
| Insulins | 1 | 2020 | 18 | 0.620 |
Why?
|
| United States | 29 | 2025 | 11859 | 0.620 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 51 | 0.620 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 88 | 0.610 |
Why?
|
| Coronary Circulation | 6 | 2004 | 189 | 0.600 |
Why?
|
| Cardiac Catheterization | 3 | 2014 | 621 | 0.600 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 139 | 0.590 |
Why?
|
| Education, Medical, Graduate | 5 | 2022 | 552 | 0.590 |
Why?
|
| Career Mobility | 1 | 2019 | 51 | 0.580 |
Why?
|
| Fibrosis | 3 | 2020 | 417 | 0.570 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 2 | 2018 | 15 | 0.570 |
Why?
|
| Employee Performance Appraisal | 1 | 2018 | 12 | 0.570 |
Why?
|
| Relative Value Scales | 1 | 2018 | 13 | 0.560 |
Why?
|
| Aortic Valve | 10 | 2023 | 451 | 0.560 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 351 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 363 | 0.560 |
Why?
|
| Kidney | 1 | 2025 | 1277 | 0.560 |
Why?
|
| Risk Assessment | 17 | 2025 | 3672 | 0.550 |
Why?
|
| Thrombosis | 6 | 2022 | 497 | 0.550 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2020 | 1104 | 0.550 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 202 | 0.540 |
Why?
|
| Gene Silencing | 2 | 2018 | 231 | 0.540 |
Why?
|
| Medical Errors | 1 | 2019 | 145 | 0.540 |
Why?
|
| Mentoring | 1 | 2019 | 84 | 0.530 |
Why?
|
| Blood Loss, Surgical | 7 | 2024 | 167 | 0.530 |
Why?
|
| Cardiomyoplasty | 3 | 2007 | 4 | 0.530 |
Why?
|
| Trans-Activators | 2 | 2018 | 701 | 0.520 |
Why?
|
| Myogenic Regulatory Factors | 2 | 2014 | 14 | 0.520 |
Why?
|
| Zebrafish | 1 | 2020 | 417 | 0.510 |
Why?
|
| Leadership | 2 | 2016 | 244 | 0.510 |
Why?
|
| Lentivirus | 1 | 2017 | 81 | 0.510 |
Why?
|
| Anticoagulants | 5 | 2023 | 602 | 0.500 |
Why?
|
| Internship and Residency | 6 | 2023 | 1219 | 0.500 |
Why?
|
| Sp1 Transcription Factor | 1 | 2016 | 38 | 0.500 |
Why?
|
| Risk Factors | 36 | 2025 | 10941 | 0.490 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2020 | 150 | 0.490 |
Why?
|
| Quality of Life | 3 | 2023 | 2081 | 0.490 |
Why?
|
| Hospital Mortality | 7 | 2025 | 1059 | 0.490 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2014 | 42 | 0.490 |
Why?
|
| Ischemia | 6 | 2005 | 358 | 0.490 |
Why?
|
| Myoblasts, Skeletal | 2 | 2007 | 9 | 0.480 |
Why?
|
| Tropical Medicine | 1 | 2017 | 104 | 0.480 |
Why?
|
| Motivation | 1 | 2018 | 328 | 0.480 |
Why?
|
| Editorial Policies | 2 | 2014 | 50 | 0.470 |
Why?
|
| Brain Death | 3 | 2025 | 73 | 0.470 |
Why?
|
| Phosphoproteins | 1 | 2018 | 452 | 0.460 |
Why?
|
| Mitral Valve Insufficiency | 5 | 2024 | 178 | 0.460 |
Why?
|
| Blood Transfusion, Autologous | 6 | 1998 | 36 | 0.460 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2015 | 10 | 0.460 |
Why?
|
| Angiogenic Proteins | 2 | 2007 | 15 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 276 | 0.460 |
Why?
|
| Equipment Design | 2 | 2014 | 536 | 0.450 |
Why?
|
| MEF2 Transcription Factors | 4 | 2017 | 34 | 0.450 |
Why?
|
| Radial Artery | 2 | 2015 | 33 | 0.450 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 693 | 0.450 |
Why?
|
| Cold Ischemia | 2 | 2025 | 28 | 0.450 |
Why?
|
| Education, Medical | 2 | 2016 | 293 | 0.440 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 222 | 0.440 |
Why?
|
| Heart Arrest, Induced | 4 | 2024 | 74 | 0.440 |
Why?
|
| Retrospective Studies | 38 | 2025 | 17516 | 0.440 |
Why?
|
| Diffusion of Innovation | 4 | 2017 | 84 | 0.440 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2024 | 192 | 0.440 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 82 | 0.430 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 222 | 0.430 |
Why?
|
| Neglected Diseases | 1 | 2017 | 152 | 0.430 |
Why?
|
| Mitral Valve Annuloplasty | 3 | 2019 | 15 | 0.430 |
Why?
|
| Patient Safety | 1 | 2019 | 444 | 0.420 |
Why?
|
| Hyaluronic Acid | 1 | 2015 | 109 | 0.420 |
Why?
|
| Angina Pectoris | 3 | 2024 | 56 | 0.420 |
Why?
|
| Curriculum | 6 | 2023 | 787 | 0.410 |
Why?
|
| Cell Differentiation | 4 | 2024 | 1921 | 0.410 |
Why?
|
| Heparin | 5 | 1997 | 203 | 0.410 |
Why?
|
| Ticlopidine | 1 | 2013 | 28 | 0.400 |
Why?
|
| Platelet Function Tests | 1 | 2013 | 38 | 0.400 |
Why?
|
| Comprehension | 1 | 2014 | 79 | 0.400 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2016 | 747 | 0.400 |
Why?
|
| Transfusion Reaction | 1 | 2013 | 42 | 0.400 |
Why?
|
| Cell Membrane | 2 | 2025 | 451 | 0.390 |
Why?
|
| Blood Platelets | 3 | 2022 | 314 | 0.390 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2013 | 47 | 0.390 |
Why?
|
| Bioprosthesis | 3 | 2023 | 110 | 0.390 |
Why?
|
| Prospective Studies | 17 | 2025 | 6438 | 0.380 |
Why?
|
| Fibrinolysis | 3 | 2022 | 44 | 0.380 |
Why?
|
| Follow-Up Studies | 13 | 2024 | 5162 | 0.370 |
Why?
|
| Ventricular Function | 1 | 2012 | 82 | 0.370 |
Why?
|
| Machine Learning | 4 | 2024 | 381 | 0.370 |
Why?
|
| Hospitals, Veterans | 3 | 2021 | 340 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2007 | 363 | 0.360 |
Why?
|
| International Cooperation | 2 | 2024 | 160 | 0.360 |
Why?
|
| Cells, Cultured | 9 | 2020 | 2895 | 0.360 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 955 | 0.350 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 1122 | 0.350 |
Why?
|
| Adult | 36 | 2025 | 31121 | 0.350 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 461 | 0.350 |
Why?
|
| Elective Surgical Procedures | 4 | 2017 | 163 | 0.350 |
Why?
|
| Heart Valve Diseases | 3 | 2019 | 165 | 0.340 |
Why?
|
| Informed Consent | 1 | 2014 | 349 | 0.340 |
Why?
|
| Hemostatics | 3 | 2022 | 58 | 0.340 |
Why?
|
| Tissue Donors | 5 | 2025 | 500 | 0.340 |
Why?
|
| Exercise Tolerance | 4 | 2024 | 90 | 0.340 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2016 | 695 | 0.330 |
Why?
|
| Quality Indicators, Health Care | 3 | 2024 | 237 | 0.330 |
Why?
|
| DNA-Binding Proteins | 6 | 2024 | 1947 | 0.330 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 292 | 0.320 |
Why?
|
| Rats, Inbred F344 | 4 | 2014 | 99 | 0.310 |
Why?
|
| Length of Stay | 7 | 2025 | 1398 | 0.310 |
Why?
|
| MicroRNAs | 1 | 2016 | 889 | 0.310 |
Why?
|
| Angiogenesis Inducing Agents | 4 | 2021 | 19 | 0.310 |
Why?
|
| Hemodynamics | 3 | 2025 | 805 | 0.300 |
Why?
|
| Fibroblast Growth Factor 1 | 5 | 1997 | 13 | 0.300 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2021 | 225 | 0.300 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 197 | 0.300 |
Why?
|
| History, 20th Century | 4 | 2015 | 360 | 0.300 |
Why?
|
| Hospitals, Low-Volume | 3 | 2019 | 35 | 0.300 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 6786 | 0.300 |
Why?
|
| Early Growth Response Protein 1 | 3 | 2005 | 38 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 1271 | 0.290 |
Why?
|
| Aorta, Thoracic | 5 | 2017 | 528 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2099 | 0.280 |
Why?
|
| Aortic Diseases | 3 | 2015 | 188 | 0.280 |
Why?
|
| Pyroptosis | 2 | 2025 | 35 | 0.280 |
Why?
|
| Endothelial Cells | 3 | 2021 | 521 | 0.280 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2021 | 146 | 0.280 |
Why?
|
| Program Development | 3 | 2021 | 181 | 0.270 |
Why?
|
| Christianity | 3 | 1997 | 15 | 0.270 |
Why?
|
| Swine | 8 | 2016 | 1185 | 0.270 |
Why?
|
| Anesthesia | 2 | 2008 | 209 | 0.270 |
Why?
|
| Stem Cells | 1 | 2013 | 703 | 0.270 |
Why?
|
| Religion and Medicine | 2 | 1997 | 26 | 0.260 |
Why?
|
| Disease Models, Animal | 12 | 2016 | 4664 | 0.260 |
Why?
|
| Ventricular Remodeling | 3 | 2021 | 153 | 0.260 |
Why?
|
| Flow Cytometry | 2 | 2021 | 766 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 1074 | 0.250 |
Why?
|
| Coronary Vessels | 4 | 2013 | 524 | 0.250 |
Why?
|
| Immediate-Early Proteins | 2 | 2004 | 57 | 0.250 |
Why?
|
| Incidence | 10 | 2025 | 3316 | 0.250 |
Why?
|
| Thoracotomy | 4 | 2019 | 107 | 0.240 |
Why?
|
| Reoperation | 7 | 2024 | 818 | 0.240 |
Why?
|
| Tissue and Organ Procurement | 2 | 2021 | 254 | 0.240 |
Why?
|
| Femoral Artery | 2 | 2004 | 134 | 0.240 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 2 | 2017 | 29 | 0.240 |
Why?
|
| American Heart Association | 1 | 2008 | 337 | 0.230 |
Why?
|
| Logistic Models | 5 | 2016 | 1799 | 0.230 |
Why?
|
| Pancuronium | 2 | 2003 | 5 | 0.230 |
Why?
|
| Androstanols | 2 | 2003 | 8 | 0.230 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 2 | 2003 | 11 | 0.230 |
Why?
|
| Protein Isoforms | 5 | 2013 | 423 | 0.230 |
Why?
|
| Anesthesia Recovery Period | 2 | 2003 | 23 | 0.230 |
Why?
|
| Survival Rate | 9 | 2020 | 2110 | 0.230 |
Why?
|
| Organ Preservation Solutions | 1 | 2025 | 21 | 0.230 |
Why?
|
| Mice | 18 | 2024 | 18207 | 0.230 |
Why?
|
| Radiography | 4 | 2016 | 743 | 0.230 |
Why?
|
| Cell Transplantation | 2 | 2005 | 37 | 0.220 |
Why?
|
| Recovery of Function | 4 | 2024 | 444 | 0.220 |
Why?
|
| Hindlimb | 3 | 2004 | 72 | 0.220 |
Why?
|
| Research Support as Topic | 1 | 2025 | 62 | 0.220 |
Why?
|
| Ileostomy | 1 | 2025 | 30 | 0.220 |
Why?
|
| Vasoplegia | 1 | 2025 | 19 | 0.220 |
Why?
|
| Arteries | 1 | 2005 | 209 | 0.210 |
Why?
|
| Arterial Pressure | 1 | 2025 | 131 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 3031 | 0.210 |
Why?
|
| Fibroblast Growth Factors | 3 | 2004 | 171 | 0.210 |
Why?
|
| Delirium | 1 | 2025 | 66 | 0.210 |
Why?
|
| Growth Substances | 3 | 1989 | 99 | 0.210 |
Why?
|
| Fluid Therapy | 1 | 2025 | 146 | 0.210 |
Why?
|
| Extracorporeal Circulation | 1 | 2004 | 46 | 0.210 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 53 | 0.200 |
Why?
|
| Program Evaluation | 2 | 2016 | 443 | 0.200 |
Why?
|
| Databases, Factual | 5 | 2025 | 1223 | 0.200 |
Why?
|
| Thromboembolism | 2 | 2022 | 94 | 0.200 |
Why?
|
| Omentum | 2 | 1997 | 40 | 0.200 |
Why?
|
| Echocardiography | 7 | 2018 | 1127 | 0.200 |
Why?
|
| Prosthesis-Related Infections | 1 | 2025 | 186 | 0.200 |
Why?
|
| Hospital Departments | 1 | 2023 | 15 | 0.200 |
Why?
|
| Social Class | 1 | 2025 | 210 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2017 | 541 | 0.190 |
Why?
|
| Foreign Bodies | 1 | 2024 | 96 | 0.190 |
Why?
|
| Texas | 6 | 2020 | 3643 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2024 | 511 | 0.190 |
Why?
|
| Heart Valves | 3 | 2019 | 51 | 0.190 |
Why?
|
| Fetal Heart | 1 | 2004 | 131 | 0.190 |
Why?
|
| Transfection | 2 | 2012 | 959 | 0.190 |
Why?
|
| Aftercare | 2 | 2021 | 151 | 0.190 |
Why?
|
| Preoperative Care | 4 | 2014 | 356 | 0.180 |
Why?
|
| Arteriosclerosis | 2 | 2000 | 110 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 666 | 0.180 |
Why?
|
| Schools, Medical | 1 | 2023 | 116 | 0.180 |
Why?
|
| Zinc Fingers | 2 | 2017 | 116 | 0.180 |
Why?
|
| Mitochondrial Diseases | 1 | 2024 | 152 | 0.180 |
Why?
|
| Medicare | 2 | 2022 | 436 | 0.180 |
Why?
|
| Drug Delivery Systems | 2 | 2021 | 216 | 0.170 |
Why?
|
| Coronary Aneurysm | 1 | 2002 | 35 | 0.170 |
Why?
|
| Phospholipids | 1 | 2022 | 99 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 397 | 0.170 |
Why?
|
| Coculture Techniques | 1 | 2021 | 230 | 0.170 |
Why?
|
| Cell Separation | 1 | 2021 | 220 | 0.170 |
Why?
|
| Cell Plasticity | 1 | 2021 | 41 | 0.170 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 323 | 0.170 |
Why?
|
| Cyclohexanones | 1 | 2020 | 18 | 0.170 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 755 | 0.170 |
Why?
|
| Knowledge | 1 | 2021 | 48 | 0.170 |
Why?
|
| Cardioplegic Solutions | 1 | 2021 | 18 | 0.170 |
Why?
|
| Nerve Block | 1 | 2002 | 68 | 0.160 |
Why?
|
| Age Factors | 3 | 2023 | 2828 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 773 | 0.160 |
Why?
|
| Adenoviruses, Human | 4 | 2002 | 97 | 0.160 |
Why?
|
| Pericardial Window Techniques | 1 | 2020 | 5 | 0.160 |
Why?
|
| Aspirin | 1 | 2022 | 214 | 0.160 |
Why?
|
| Transplantation, Heterotopic | 1 | 2020 | 15 | 0.160 |
Why?
|
| Coronavirus | 1 | 2020 | 28 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 282 | 0.160 |
Why?
|
| Veterans | 4 | 2021 | 1753 | 0.160 |
Why?
|
| Self Care | 1 | 2002 | 230 | 0.160 |
Why?
|
| Sugars | 1 | 2020 | 17 | 0.160 |
Why?
|
| Glucose | 2 | 2025 | 853 | 0.160 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 4 | 2001 | 97 | 0.160 |
Why?
|
| Critical Care | 4 | 2004 | 684 | 0.160 |
Why?
|
| Genomics | 1 | 2008 | 1612 | 0.150 |
Why?
|
| Receptors, Steroid | 1 | 2020 | 167 | 0.150 |
Why?
|
| Diuretics | 1 | 2020 | 157 | 0.150 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.150 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 72 | 0.150 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 74 | 0.150 |
Why?
|
| Radiopharmaceuticals | 4 | 2022 | 162 | 0.150 |
Why?
|
| Thrombopoietin | 1 | 1999 | 30 | 0.150 |
Why?
|
| Exercise Test | 4 | 2023 | 237 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 352 | 0.150 |
Why?
|
| Transgenes | 2 | 1999 | 320 | 0.150 |
Why?
|
| Pyridines | 1 | 2020 | 256 | 0.150 |
Why?
|
| Leiomyosarcoma | 1 | 1999 | 22 | 0.150 |
Why?
|
| Biomarkers | 3 | 2025 | 3382 | 0.150 |
Why?
|
| Triage | 1 | 2020 | 143 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 2 | 2021 | 545 | 0.150 |
Why?
|
| Potassium | 1 | 2020 | 268 | 0.150 |
Why?
|
| Mitochondria | 1 | 2024 | 777 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2020 | 231 | 0.140 |
Why?
|
| Intensive Care Units | 2 | 2020 | 525 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 209 | 0.140 |
Why?
|
| Cell Survival | 3 | 2007 | 830 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2020 | 217 | 0.140 |
Why?
|
| Splenic Diseases | 1 | 2018 | 28 | 0.140 |
Why?
|
| Angiography | 2 | 2015 | 181 | 0.140 |
Why?
|
| Phenotype | 2 | 2020 | 4471 | 0.140 |
Why?
|
| Pandemics | 3 | 2020 | 1160 | 0.140 |
Why?
|
| Staphylococcus epidermidis | 1 | 2018 | 39 | 0.140 |
Why?
|
| Frailty | 1 | 2021 | 140 | 0.140 |
Why?
|
| Consumer Health Information | 1 | 2018 | 28 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 227 | 0.140 |
Why?
|
| Aprotinin | 2 | 1995 | 9 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1288 | 0.140 |
Why?
|
| Hemodilution | 1 | 1998 | 13 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 151 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2024 | 4669 | 0.140 |
Why?
|
| Animals, Newborn | 1 | 2021 | 1014 | 0.140 |
Why?
|
| Patient Selection | 3 | 2020 | 719 | 0.140 |
Why?
|
| Stroke | 2 | 2024 | 1055 | 0.140 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2018 | 39 | 0.140 |
Why?
|
| Models, Animal | 2 | 2014 | 450 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 1209 | 0.140 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 2337 | 0.130 |
Why?
|
| Emergency Treatment | 2 | 2016 | 82 | 0.130 |
Why?
|
| Blood Component Transfusion | 1 | 1998 | 58 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 228 | 0.130 |
Why?
|
| Elephantiasis, Filarial | 1 | 2017 | 12 | 0.130 |
Why?
|
| Heart Neoplasms | 1 | 1999 | 108 | 0.130 |
Why?
|
| Brachiocephalic Trunk | 1 | 2017 | 35 | 0.130 |
Why?
|
| Dexamethasone | 1 | 1999 | 250 | 0.130 |
Why?
|
| Trachoma | 1 | 2017 | 13 | 0.130 |
Why?
|
| Trauma Centers | 1 | 2019 | 206 | 0.130 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 302 | 0.130 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 543 | 0.130 |
Why?
|
| Axillary Artery | 1 | 2017 | 31 | 0.130 |
Why?
|
| Workload | 1 | 2019 | 149 | 0.130 |
Why?
|
| Hematocrit | 5 | 1998 | 104 | 0.130 |
Why?
|
| Mass Drug Administration | 1 | 2017 | 14 | 0.130 |
Why?
|
| Sepsis | 1 | 2022 | 494 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 21 | 0.130 |
Why?
|
| Snail Family Transcription Factors | 1 | 2017 | 27 | 0.130 |
Why?
|
| Abscess | 1 | 2018 | 137 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 1 | 2018 | 127 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 336 | 0.130 |
Why?
|
| Hemostatic Techniques | 1 | 2017 | 26 | 0.130 |
Why?
|
| Fibronectins | 1 | 2017 | 99 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 151 | 0.130 |
Why?
|
| Collagen Type I | 1 | 2017 | 110 | 0.130 |
Why?
|
| Erythropoietin | 2 | 1994 | 103 | 0.130 |
Why?
|
| Endothelium, Vascular | 4 | 2004 | 466 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1999 | 299 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 205 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2021 | 1481 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2016 | 5047 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1374 | 0.120 |
Why?
|
| Troponin T | 1 | 2018 | 254 | 0.120 |
Why?
|
| Histones | 2 | 2017 | 542 | 0.120 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 121 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 564 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 170 | 0.120 |
Why?
|
| Comorbidity | 6 | 2022 | 1584 | 0.120 |
Why?
|
| Palliative Care | 1 | 2020 | 445 | 0.120 |
Why?
|
| Ontario | 1 | 2015 | 84 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2015 | 110 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 1999 | 1540 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 535 | 0.110 |
Why?
|
| Self Report | 1 | 2019 | 555 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1390 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2016 | 809 | 0.110 |
Why?
|
| Technetium Tc 99m Sestamibi | 3 | 2001 | 24 | 0.110 |
Why?
|
| Transformation, Genetic | 1 | 1995 | 28 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2015 | 70 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 511 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2017 | 648 | 0.110 |
Why?
|
| North America | 1 | 2016 | 257 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2016 | 184 | 0.110 |
Why?
|
| 3T3 Cells | 1 | 1995 | 119 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2017 | 245 | 0.110 |
Why?
|
| Indocyanine Green | 1 | 2015 | 51 | 0.110 |
Why?
|
| Registries | 3 | 2020 | 1609 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 1318 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2015 | 256 | 0.110 |
Why?
|
| Catheterization | 2 | 1994 | 223 | 0.110 |
Why?
|
| Mentors | 1 | 2016 | 168 | 0.110 |
Why?
|
| Prevalence | 1 | 2021 | 2687 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1589 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2019 | 558 | 0.110 |
Why?
|
| Brain | 2 | 2025 | 3168 | 0.110 |
Why?
|
| Robotics | 1 | 2016 | 102 | 0.110 |
Why?
|
| Leukemia | 1 | 2017 | 374 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2016 | 1210 | 0.100 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 1219 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2025 | 2293 | 0.100 |
Why?
|
| Prognosis | 6 | 2020 | 4859 | 0.100 |
Why?
|
| Coronary Angiography | 3 | 2002 | 453 | 0.100 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2013 | 9 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1166 | 0.100 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Embolism | 1 | 1994 | 38 | 0.100 |
Why?
|
| Propensity Score | 3 | 2024 | 271 | 0.100 |
Why?
|
| Tracheostomy | 1 | 1996 | 211 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 722 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 2 | 2024 | 142 | 0.100 |
Why?
|
| Surgical Flaps | 1 | 2015 | 179 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 3 | 2002 | 74 | 0.100 |
Why?
|
| Mental Recall | 1 | 2014 | 136 | 0.100 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2014 | 69 | 0.100 |
Why?
|
| Endocardial Cushion Defects | 1 | 1993 | 7 | 0.100 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 1217 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2017 | 558 | 0.100 |
Why?
|
| New York | 1 | 2013 | 69 | 0.100 |
Why?
|
| Thrombocytopenia | 1 | 1994 | 217 | 0.100 |
Why?
|
| Models, Cardiovascular | 2 | 2004 | 166 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 636 | 0.090 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1993 | 128 | 0.090 |
Why?
|
| Liver | 1 | 2020 | 1787 | 0.090 |
Why?
|
| Fibrin | 2 | 2022 | 64 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 413 | 0.090 |
Why?
|
| Cystic Fibrosis | 4 | 2002 | 265 | 0.090 |
Why?
|
| Inflammation | 4 | 2023 | 1483 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2014 | 1016 | 0.090 |
Why?
|
| Colonic Neoplasms | 4 | 2002 | 263 | 0.090 |
Why?
|
| Graft Survival | 3 | 2021 | 460 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2013 | 212 | 0.090 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2005 | 100 | 0.090 |
Why?
|
| Placebos | 1 | 2012 | 224 | 0.090 |
Why?
|
| Ligation | 2 | 2004 | 131 | 0.090 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 1993 | 132 | 0.090 |
Why?
|
| Mitogens | 2 | 1989 | 30 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 5 | 2018 | 4715 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1991 | 59 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2001 | 47 | 0.080 |
Why?
|
| Educational Status | 2 | 2023 | 276 | 0.080 |
Why?
|
| Abdomen | 2 | 1997 | 128 | 0.080 |
Why?
|
| Hepatic Duct, Common | 1 | 1990 | 5 | 0.080 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 1990 | 7 | 0.080 |
Why?
|
| Adipose Tissue | 3 | 1998 | 499 | 0.080 |
Why?
|
| Cholangitis | 1 | 1990 | 38 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 1991 | 141 | 0.080 |
Why?
|
| Communication | 1 | 2014 | 539 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2014 | 1449 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2012 | 1622 | 0.070 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2000 | 125 | 0.070 |
Why?
|
| Heart Ventricles | 3 | 2021 | 758 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 574 | 0.070 |
Why?
|
| Perfusion | 2 | 2014 | 211 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 736 | 0.070 |
Why?
|
| Collateral Circulation | 2 | 2000 | 41 | 0.070 |
Why?
|
| Immune Tolerance | 1 | 1990 | 155 | 0.070 |
Why?
|
| Eosinophilia | 1 | 1990 | 110 | 0.070 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2002 | 245 | 0.070 |
Why?
|
| Aneurysm | 1 | 1989 | 66 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1990 | 218 | 0.070 |
Why?
|
| Hypothermia, Induced | 2 | 2024 | 170 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 4027 | 0.070 |
Why?
|
| Shock | 1 | 1989 | 97 | 0.070 |
Why?
|
| Prosthesis Design | 2 | 2023 | 619 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 917 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 1988 | 130 | 0.060 |
Why?
|
| Photomicrography | 1 | 2007 | 10 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2025 | 2062 | 0.060 |
Why?
|
| Pericardium | 2 | 2021 | 103 | 0.060 |
Why?
|
| Stomach | 1 | 1989 | 269 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2562 | 0.060 |
Why?
|
| Methods | 2 | 1999 | 95 | 0.060 |
Why?
|
| Organ Size | 2 | 2025 | 412 | 0.060 |
Why?
|
| Femoral Vein | 2 | 1998 | 43 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 305 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 204 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 1989 | 221 | 0.060 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2025 | 16 | 0.060 |
Why?
|
| Procaine | 1 | 2025 | 12 | 0.060 |
Why?
|
| Caspase 1 | 1 | 2025 | 49 | 0.060 |
Why?
|
| Disaccharides | 1 | 2025 | 19 | 0.060 |
Why?
|
| Mannitol | 1 | 2025 | 40 | 0.060 |
Why?
|
| Glutamates | 1 | 2025 | 51 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 677 | 0.060 |
Why?
|
| Histidine | 1 | 2025 | 69 | 0.060 |
Why?
|
| Electrolytes | 1 | 2025 | 59 | 0.060 |
Why?
|
| Cattle | 2 | 2022 | 501 | 0.060 |
Why?
|
| Coenzyme A Ligases | 1 | 2025 | 13 | 0.060 |
Why?
|
| Florida | 1 | 2025 | 72 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2005 | 187 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 936 | 0.060 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2005 | 38 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2018 | 3831 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2960 | 0.060 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2005 | 37 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2005 | 40 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2025 | 89 | 0.050 |
Why?
|
| Homeobox Protein Nkx-2.5 | 1 | 2024 | 20 | 0.050 |
Why?
|
| Rheumatic Heart Disease | 1 | 2005 | 38 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2025 | 92 | 0.050 |
Why?
|
| Adenylyl Cyclases | 1 | 2005 | 53 | 0.050 |
Why?
|
| Muscle Weakness | 2 | 2003 | 90 | 0.050 |
Why?
|
| Nucleoside Deaminases | 5 | 2002 | 23 | 0.050 |
Why?
|
| Parvalbumins | 1 | 2005 | 35 | 0.050 |
Why?
|
| Cytosine Deaminase | 5 | 2002 | 15 | 0.050 |
Why?
|
| Multipotent Stem Cells | 1 | 2024 | 28 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 127 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2004 | 234 | 0.050 |
Why?
|
| Atrophy | 1 | 2025 | 248 | 0.050 |
Why?
|
| Muscle, Skeletal | 2 | 2003 | 999 | 0.050 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 710 | 0.050 |
Why?
|
| Glutathione | 1 | 2025 | 201 | 0.050 |
Why?
|
| Histone Demethylases | 2 | 2015 | 41 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2005 | 180 | 0.050 |
Why?
|
| Heart Septum | 1 | 2004 | 44 | 0.050 |
Why?
|
| Neutralization Tests | 3 | 2002 | 226 | 0.050 |
Why?
|
| Calcinosis | 1 | 2005 | 180 | 0.050 |
Why?
|
| Adolescent | 7 | 2020 | 20718 | 0.050 |
Why?
|
| Gene Expression | 3 | 2005 | 1486 | 0.050 |
Why?
|
| Heart Atria | 2 | 1999 | 335 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2025 | 535 | 0.050 |
Why?
|
| Tuberculosis | 1 | 1990 | 554 | 0.050 |
Why?
|
| Motion | 1 | 2023 | 36 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2005 | 322 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2024 | 105 | 0.050 |
Why?
|
| NADPH Oxidases | 1 | 2024 | 109 | 0.050 |
Why?
|
| Myoblasts | 1 | 2003 | 33 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 270 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 573 | 0.050 |
Why?
|
| Death | 1 | 2024 | 77 | 0.050 |
Why?
|
| Algorithms | 3 | 2021 | 1659 | 0.050 |
Why?
|
| Extracellular Space | 1 | 2022 | 79 | 0.050 |
Why?
|
| Hand | 1 | 2023 | 94 | 0.050 |
Why?
|
| Anastomosis, Surgical | 1 | 2023 | 176 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 68 | 0.050 |
Why?
|
| Homozygote | 1 | 2004 | 535 | 0.050 |
Why?
|
| Edema | 1 | 2023 | 133 | 0.050 |
Why?
|
| Vimentin | 1 | 2022 | 59 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2025 | 165 | 0.050 |
Why?
|
| Nervous System | 1 | 2003 | 118 | 0.050 |
Why?
|
| Postoperative Care | 2 | 2002 | 294 | 0.050 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2022 | 6 | 0.050 |
Why?
|
| Health Policy | 1 | 2024 | 224 | 0.050 |
Why?
|
| Forecasting | 2 | 2018 | 350 | 0.040 |
Why?
|
| Iron | 1 | 2025 | 306 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2022 | 170 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2022 | 55 | 0.040 |
Why?
|
| Acute Disease | 2 | 2015 | 1145 | 0.040 |
Why?
|
| Financing, Organized | 1 | 2021 | 21 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2004 | 767 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2025 | 383 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1487 | 0.040 |
Why?
|
| Peptides | 1 | 2005 | 704 | 0.040 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 4 | 2002 | 48 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 85 | 0.040 |
Why?
|
| Accreditation | 1 | 2021 | 85 | 0.040 |
Why?
|
| Wrist | 1 | 2021 | 28 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 174 | 0.040 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2002 | 132 | 0.040 |
Why?
|
| Endocardium | 1 | 2001 | 46 | 0.040 |
Why?
|
| Donor Selection | 1 | 2021 | 57 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2020 | 50 | 0.040 |
Why?
|
| Europe | 1 | 2002 | 366 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 47 | 0.040 |
Why?
|
| Adenosine | 1 | 2001 | 118 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 288 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 396 | 0.040 |
Why?
|
| Tomography, Emission-Computed | 1 | 2000 | 35 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2001 | 96 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2021 | 88 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 218 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2000 | 49 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2002 | 410 | 0.040 |
Why?
|
| Homeostasis | 1 | 2004 | 713 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 9988 | 0.040 |
Why?
|
| Safety | 2 | 2002 | 214 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2001 | 154 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 49 | 0.040 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1997 | 61 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 183 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2020 | 318 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 331 | 0.040 |
Why?
|
| Fear | 1 | 2021 | 192 | 0.040 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 47 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2021 | 116 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 666 | 0.040 |
Why?
|
| Intraoperative Care | 2 | 1998 | 122 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2018 | 828 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 589 | 0.040 |
Why?
|
| Diverticulum | 1 | 1999 | 23 | 0.040 |
Why?
|
| Injections | 1 | 1999 | 111 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 36 | 0.040 |
Why?
|
| Serum Response Factor | 1 | 1999 | 30 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2018 | 948 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 182 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 1999 | 56 | 0.040 |
Why?
|
| Androstadienes | 1 | 1999 | 50 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 148 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2000 | 167 | 0.040 |
Why?
|
| Sternotomy | 1 | 2019 | 42 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2002 | 286 | 0.040 |
Why?
|
| Organizational Policy | 1 | 2019 | 50 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2018 | 24 | 0.040 |
Why?
|
| Anxiety | 1 | 2005 | 1008 | 0.040 |
Why?
|
| Rats, Inbred Strains | 2 | 1989 | 181 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 995 | 0.040 |
Why?
|
| Access to Information | 1 | 2018 | 46 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1999 | 147 | 0.030 |
Why?
|
| Health Communication | 1 | 2018 | 31 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 225 | 0.030 |
Why?
|
| Health Education | 1 | 2020 | 228 | 0.030 |
Why?
|
| Flavonoids | 1 | 1999 | 83 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2018 | 46 | 0.030 |
Why?
|
| Long-Term Synaptic Depression | 1 | 2018 | 11 | 0.030 |
Why?
|
| Microspheres | 1 | 1998 | 67 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1998 | 115 | 0.030 |
Why?
|
| Noble Gases | 1 | 1997 | 2 | 0.030 |
Why?
|
| Endoderm | 1 | 2018 | 23 | 0.030 |
Why?
|
| Ectoderm | 1 | 2018 | 31 | 0.030 |
Why?
|
| Holmium | 1 | 1997 | 9 | 0.030 |
Why?
|
| Lactates | 1 | 1998 | 81 | 0.030 |
Why?
|
| Capillaries | 1 | 1998 | 64 | 0.030 |
Why?
|
| Mouse Embryonic Stem Cells | 1 | 2018 | 31 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2019 | 85 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 1999 | 576 | 0.030 |
Why?
|
| Iliac Artery | 1 | 1998 | 63 | 0.030 |
Why?
|
| Dependovirus | 1 | 1999 | 161 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 1998 | 185 | 0.030 |
Why?
|
| Observer Variation | 1 | 2018 | 309 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2001 | 811 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 1998 | 158 | 0.030 |
Why?
|
| Mesoderm | 1 | 2018 | 104 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2001 | 2552 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 227 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1997 | 37 | 0.030 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 1998 | 101 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 191 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1999 | 416 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2017 | 70 | 0.030 |
Why?
|
| RNA | 1 | 2020 | 514 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 1456 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2020 | 533 | 0.030 |
Why?
|
| Sheep | 1 | 1997 | 219 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1997 | 47 | 0.030 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 1997 | 26 | 0.030 |
Why?
|
| Perception | 1 | 2018 | 229 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 625 | 0.030 |
Why?
|
| Erythrocyte Volume | 1 | 1996 | 3 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2017 | 134 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 3471 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 2002 | 1171 | 0.030 |
Why?
|
| Child | 4 | 2021 | 26097 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 692 | 0.030 |
Why?
|
| Liver Neoplasms | 3 | 2002 | 1362 | 0.030 |
Why?
|
| Cell Division | 2 | 1988 | 718 | 0.030 |
Why?
|
| Depression | 1 | 2005 | 1316 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 661 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 273 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 559 | 0.030 |
Why?
|
| Management Quality Circles | 1 | 1996 | 1 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2018 | 591 | 0.030 |
Why?
|
| Gastroepiploic Artery | 1 | 2015 | 1 | 0.030 |
Why?
|
| Lung | 2 | 2001 | 1535 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2018 | 221 | 0.030 |
Why?
|
| Immunity | 1 | 1997 | 179 | 0.030 |
Why?
|
| Operating Rooms | 1 | 1996 | 74 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 259 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 1366 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 1996 | 341 | 0.030 |
Why?
|
| Silicones | 1 | 2015 | 30 | 0.030 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1995 | 38 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 725 | 0.030 |
Why?
|
| Dogs | 1 | 1996 | 616 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1996 | 242 | 0.030 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2015 | 63 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2015 | 18 | 0.030 |
Why?
|
| Renal Insufficiency | 2 | 2014 | 256 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2015 | 31 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1996 | 77 | 0.030 |
Why?
|
| Hypoxia | 1 | 1997 | 247 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 502 | 0.030 |
Why?
|
| Ancrod | 1 | 1994 | 3 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2015 | 77 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 159 | 0.030 |
Why?
|
| Lasers | 1 | 2015 | 111 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1996 | 452 | 0.030 |
Why?
|
| Infant | 3 | 2017 | 13239 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2088 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1996 | 182 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 301 | 0.030 |
Why?
|
| Embolectomy | 1 | 1994 | 8 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1994 | 93 | 0.030 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 1675 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 382 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 584 | 0.030 |
Why?
|
| DNA Modification Methylases | 1 | 2013 | 44 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2014 | 43 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1993 | 41 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2017 | 408 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 966 | 0.020 |
Why?
|
| Virus Replication | 1 | 1996 | 607 | 0.020 |
Why?
|
| Vascular Patency | 1 | 1993 | 178 | 0.020 |
Why?
|
| Lysine | 1 | 2013 | 164 | 0.020 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 1993 | 34 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3795 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 554 | 0.020 |
Why?
|
| Alternative Splicing | 2 | 2005 | 310 | 0.020 |
Why?
|
| Lung Diseases | 2 | 2014 | 396 | 0.020 |
Why?
|
| Ribs | 1 | 1993 | 52 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 80 | 0.020 |
Why?
|
| Plasmids | 1 | 2013 | 446 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 331 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 242 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1994 | 191 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2332 | 0.020 |
Why?
|
| Troponin I | 1 | 2013 | 122 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1993 | 175 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 998 | 0.020 |
Why?
|
| Escherichia coli | 3 | 2002 | 991 | 0.020 |
Why?
|
| Breast | 1 | 1993 | 214 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1136 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 1998 | 3362 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 1998 | 899 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 938 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1216 | 0.020 |
Why?
|
| Cholecystitis | 1 | 1990 | 20 | 0.020 |
Why?
|
| Tuberculosis, Hepatic | 1 | 1990 | 3 | 0.020 |
Why?
|
| Peritonitis, Tuberculous | 1 | 1990 | 3 | 0.020 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1990 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 600 | 0.020 |
Why?
|
| Recurrence | 1 | 1994 | 1470 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2012 | 288 | 0.020 |
Why?
|
| Amiodarone | 1 | 1989 | 48 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 1989 | 48 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1594 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2017 | 14949 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1989 | 38 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1989 | 65 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2000 | 3753 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1990 | 124 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1990 | 134 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1989 | 364 | 0.020 |
Why?
|
| Carotid Artery Injuries | 1 | 1988 | 32 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 116 | 0.020 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1989 | 161 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 3711 | 0.020 |
Why?
|
| Syndrome | 1 | 1990 | 1159 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 1988 | 124 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2464 | 0.010 |
Why?
|
| Kinetics | 1 | 1988 | 1084 | 0.010 |
Why?
|
| Blood Volume | 2 | 1996 | 73 | 0.010 |
Why?
|
| Tomography | 1 | 2005 | 33 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 236 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1798 | 0.010 |
Why?
|
| Obesity | 1 | 2016 | 2381 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1990 | 1877 | 0.010 |
Why?
|
| Aorta | 1 | 1988 | 521 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2005 | 176 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 6094 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8532 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2004 | 92 | 0.010 |
Why?
|
| Research | 1 | 2005 | 265 | 0.010 |
Why?
|
| Paralysis | 1 | 2003 | 28 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2005 | 975 | 0.010 |
Why?
|
| Ventilator Weaning | 1 | 2003 | 30 | 0.010 |
Why?
|
| Cell Line | 1 | 1988 | 2557 | 0.010 |
Why?
|
| Leg | 1 | 2004 | 119 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 307 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 29 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 2002 | 215 | 0.010 |
Why?
|
| Diet, Atherogenic | 1 | 2000 | 14 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 601 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 505 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 1999 | 29 | 0.010 |
Why?
|
| Receptors, LDL | 1 | 2000 | 106 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 1999 | 29 | 0.010 |
Why?
|
| Hematologic Tests | 1 | 1999 | 36 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1999 | 227 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 1998 | 38 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 984 | 0.010 |
Why?
|
| Glucuronidase | 1 | 1997 | 32 | 0.010 |
Why?
|
| Serotyping | 1 | 1997 | 172 | 0.010 |
Why?
|
| Base Sequence | 1 | 2000 | 2737 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1997 | 151 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1997 | 262 | 0.010 |
Why?
|
| New York City | 1 | 1996 | 60 | 0.010 |
Why?
|
| Antibodies | 1 | 1997 | 320 | 0.010 |
Why?
|
| Cost Savings | 1 | 1996 | 79 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1997 | 338 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 510 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 1993 | 235 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 1611 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1993 | 715 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1993 | 2398 | 0.000 |
Why?
|
| Anemia | 1 | 1993 | 351 | 0.000 |
Why?
|
| Cardiac Output, Low | 1 | 1989 | 59 | 0.000 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 1989 | 146 | 0.000 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1989 | 485 | 0.000 |
Why?
|